In rise of recent popularity of the buying and selling of CBD, more requirements for for CBD labeling should be mandated. In this post, we’ll cover some of the reasons why the mandates are needed and reasons why the CBD labeling requirements should be in place across the United States.
Confusion at the Airports
Though CBD is legal in the United States due to the passing of the Farm Bill in 2018, there is still confusion across the nation. For example, one article mentions the confusion of airport attendants as they question whether to confiscate CBD products from passengers. In regards to labeling of CBD products, they state:
The question arose about how TSA officers would know your product contains less than 0.3% THC. Of course, they could read the label, but imagine the lines that would form while they’re squinting at the contents, assuming it is marked that way. And therein lies some of the problem.From http://www.texarkanagazette.com
This brings a real concern. Further, the article mentions, “Not every CBD product has it (clear label), so you may need to request it.” The confusion of labeling of CBD products seems to be a real concern. After all, how is airport staff supposed to accurately assess the products and determine whether a product meets the legal guidelines of having THC? The governing bodies need to adapt to the market realities.
It’s Time for Change
It’s time to ensure accurate CBD labeling requirements are in place across the nation. Oftentimes, using QR technology this labeling requirement can provide more clarity for lab results and be trained to staff (such as airport staff). Though, in order for this change to have an impact, it must be mandated across the US– at the federal-level. The FDA has provided a presentation, though, has mandated action across the USA, yet.
If you want help understanding where the industry is headed with CBD product labeling, we can help you with consulting. Reach out and contact us for more information.
For his entire career, Dr. Ostrow has dedicated his work to ending health disparities and finding innovative solutions to the most challenging problems in public health. Trained at the University of Chicago in their Medical Scientist MD/PhD Program (MSTP) he began his research on the neuropharmacology of mood disorders, but soon found himself as the founding PI of the largest and longest running longitudinal observational study of men at-risk for AIDS, the Multicenter AIDS Cohort Study (MACS) in 1983. His research since then has focused on the links between psychoactive drugs and HIV infection, recently showing that the use of three types of drugs-stimulants, EDDs and volatile nitrites-are associated with the majority of new HIV infections among gay/bisexual men.
From his clinical practice as an Addiction Psychaitrist and his MACS research findings, he concluded that cannabis use did not have negative effects on either HIV infection or disease progression. This led him to be an early advocate for research on the therapeutic potential of medical cannabis and drug policy changes, including ending the Federal prohibition of Cannabis use and research. Currently he is focusing on translational research to develop Cannabinoid-based HIV therapies and the establishment of a Community-Based Cannabis Research Network to accelerate the development of data based MC therapeutic guidelines for specific symptoms and conditions.